scholarly journals ML-14 LOW INVASIVE APPROACH FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA TREATMENT INVOLVING RITUXIMAB–METHOTREXATE + PROCARBAZINE + VINCRISTINE AND TRIPLE INTRATHECAL INJECTION

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii35-ii35
Author(s):  
Takahiro Ogawa ◽  
Kei Oowada ◽  
Kazuna Tanba ◽  
Kouichi Hirakawa

Abstract INTRODUCTION Although the treatment outcomes of primary central nervous system lymphoma (PCNSL) with multiple treatment regimens involving high–dose methotrexate (MTX)–based multiagent chemotherapy have improved compared with the outcomes with high–dose methotrexate therapy in recent years, its regimen has not been established. Additionally, it is controversial whether intrathecal (IT) MTX injection can be included in a regimen. Our facilities treat PCNSL with R–MPV (rituximab–methotrexate + procarbazine + vincristine) and triple IT injection (methotrexate + Ara C + prednisolone). Here we report a low invasive approach for PCNSL treatment involving R–MPV therapy and triple IT injection. CASE DESCRIPTION A 58–year–old woman complained of prolonged headache and had undergone a medical checkup at our department. Head computed tomography revealed a mass lesion with edema near the right anterior horn of the lateral ventricle. After being hospitalized, biopsy was performed via a small craniotomy for the mass lesion near the right anterior horn of the lateral ventricle, which was suspected to be PCNSL. Multipurpose Head Frame 2 (Mizuho Co., Ltd.) was used for four points of head fixation. Vertek Biopsy Kit (Medtronic Co., Ltd.) was attached to it, and needle biopsy guided by neuronavigation was performed. Finally, biopsy samples were obtained from the lesion. Changes in the entry and target points could be easily made through the operative procedure, which was performed uneventfully. The diagnosis was B–cell–related lymphoma. Subsequently, an Ommaya reservoir was placed via lumbar puncture on postoperative day 7. Finally, the patient was successfully treated with R–MPV therapy and triple IT injection, thereby avoiding repeated lumbar puncture and reduced pain associated with IT injection. CONCLUSION We have reported the diagnosis of PCNSL with needle biopsy guided by neuronavigation and its treatment with R–MPV therapy and triple IT injection after lumbar Ommaya reservoir placement. This approach was associated with reduced invasion and pain in the patient.

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii120-ii121
Author(s):  
Jun-ping Zhang ◽  
Jing-jing Ge ◽  
Cheng Li ◽  
Shao-pei Qi ◽  
Feng-jun Xue ◽  
...  

Abstract OBJECTIVE To evaluate the efficacy and safety of high-dose methotrexate combined with temozolomide in the treatment of newly diagnosed primary central nervous system lymphoma. METHODS A retrospective study was performed to analyze the clinical data of patients with primary central nervous system lymphoma treated with high-dose methotrexate plus temozolomide in the Department of Neuro-oncology, Capital Medical University, Sanbo Brain Hospital from May 2010 to December 2018. RESULTS A total of 41 patients were identified. Median age was 57 years (range, 27–76 years). The maximal extent of surgery was total resection in 6, partial resection in 8, and biopsy in 27 patients. Of the 35 patients with evaluable lesions, 32 achieved complete response (CR) and 3 achieved partial response. CR rate was 91.4%. The median follow-up time was 36.5 months (range, 4.9–115.4 months). After treatment, the median progression-free survival (PFS) was 45.1 months. PFS rate at 1, 2, 5 years were 85.4%, 70.1% and 43.8%, respectively. The OS rate at 1, 2, 5 years were 92.7%, 82.4% and 66.5%, respectively. The median PFS of patients younger than 65 years was better than that of patients ≥65 years (98.8 months vs 27.9 months, p=0.039). There was no association between efficacy and extent of resection (p=0.836). After disease progression, 6 of the 21 patients received radiotherapy. There was no statistical difference in OS between the patients with or without radiotherapy (36.9 months vs 28.4 months). The main severe adverse events were myelosuppression (36.6%) and elevated transaminase (34.1%). Three patients were discontinued due to drug-related toxicities. CONCLUSIONS High-dose methotrexate combined with temozolomide is effective in the treatment of primary central nervous system lymphoma, with a low incidence of severe adverse reactions. This efficacy may be better than the historical control of methotrexate alone or methotrexate plus rituximab.


2005 ◽  
Vol 45 (12) ◽  
pp. 650-652 ◽  
Author(s):  
Keishi MAKINO ◽  
Masato KOCHI ◽  
Hideo NAKAMURA ◽  
Jun-ichiro KURODA ◽  
Yoshiteru HONDA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document